LBT Innovations (ASX:LBT) - Managing Director & CEO, Brent Barnes
Managing Director & CEO, Brent Barnes
Source: LBT Innovations
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors
  • Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares
  • The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee
  • Thats said, the policy is still subject to shareholder approval
  • On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share

LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors.

Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares.

The LBT Board knows the importance of having directors invested in the future performance of the company, which is why the new board policy has been put in place.

LBT believes the new policy will represent an ongoing commitment from all Non-Executive Directors.

The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee.

However, the policy is subject to shareholder approval. If approved, new LBT shares will be issued within one month of the annual general meeting.

“This new board policy sets a commitment to ensure all directors invest in, and support, the future of LBT Innovations,” Chairman Kate Costello said.

“This is a positive indication of the long term potential the board see in the company and builds alignment between the LBT Board and feedback received from LBT shareholders,” he added.

On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share.

LBT by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…